PIR

Pirin (PIR) is a transcriptional coregulator that links oxidative and oncogenic signaling to cell-cycle progression and inflammatory gene expression (PMID:31500513, PMID:32679705). Its basal transcription is driven by NRF2, which binds an evolutionarily conserved antioxidant response element located downstream of the PIR transcription start site, establishing PIR as a direct NRF2 target gene (PMID:24390086). PIR in turn acts on the cell cycle by binding the E2F1 promoter and activating E2F1 transcription, raising the levels of E2F1 target genes (cdk4, cdk6, cyclin D, cyclin E, and DDR1) to drive G1/S progression and promote breast cancer proliferation, migration, invasion, and metastasis (PMID:31500513). PIR is positioned downstream of upstream oncogenic and metabolic inputs: HPV16 E7 elevates PIR through an EGFR/PI3K/AKT1/NRF2 axis, and elevated PIR then activates NF-κB (PMID:32679705). Beyond these transcriptional and signaling roles, the molecular-biochemical basis of PIR's coregulatory activity has not been reconstituted in the available corpus.

1. 2014 Medium

   Established how PIR expression is controlled, identifying it as a direct NRF2 target rather than a constitutively expressed gene, thereby placing PIR within the antioxidant/redox response.

   Evidence Luciferase reporter assays with deletion constructs and ChIP for NRF2 occupancy at a conserved ARE in HeLa cells

   PMID:24390086

   Open questions at the time

   • Single study from one lab
   • Does not address what PIR does downstream once expressed
   • ARE function in non-HeLa, physiological contexts not tested
2. 2019 Medium

   Defined a downstream effector function for PIR by showing it directly activates E2F1 transcription to drive cell-cycle progression and tumor growth, moving PIR from a redox-regulated gene to a pro-proliferative transcriptional coregulator.

   Evidence shRNA knockdown, E2F1 promoter ChIP and luciferase reporter, xenograft model, and invasion/migration assays in breast cancer cells

   PMID:31500513

   Open questions at the time

   • Mechanism of PIR recruitment to the E2F1 promoter not resolved
   • Whether PIR binds DNA directly or via partners unknown
   • Single lab; no structural basis for transcriptional activation
3. 2019 Low

   Placed PIR within an inflammatory signaling cascade, showing it acts downstream of the SIRT1-SREBP1 axis to control NLRP3 inflammasome and inflammatory signaling in particulate-matter-exposed pulmonary fibroblasts.

   Evidence Microarray, pathway analysis, qPCR, Western blot, and SIRT1/SREBP1/PIR inhibitors in a PM-treated fibroblast model

   PMID:31299012

   Open questions at the time

   • Pathway placement inferred from inhibitor and expression data without biochemical reconstitution of PIR's molecular mechanism
   • Direct molecular target of PIR in inflammation not identified
   • Causality between PIR and NLRP3 not established at protein-interaction level
4. 2020 Medium

   Connected upstream oncogenic signaling to PIR, demonstrating that HPV16 E7 elevates PIR via EGFR/PI3K/AKT1/NRF2 and that PIR then activates NF-κB, integrating viral oncoprotein signaling with PIR-driven transcriptional output.

   Evidence Pharmacological inhibition of EGFR/PI3K/AKT1, knockdown/overexpression, Western blot, and reporter assays in oral cancer cells

   PMID:32679705

   Open questions at the time

   • Direct biochemical link between PIR and NF-κB activation not reconstituted
   • Whether NF-κB activation is transcriptional coregulation or indirect unclear
   • Single lab; epistasis inferred from inhibitors

• The molecular-biochemical mechanism by which PIR exerts transcriptional coregulation — its direct binding partners, whether it engages DNA directly, and the role of any cofactor in this activity — remains unresolved.
• No structural model of PIR bound to promoter or partner
• No reciprocally validated direct protein partner identified
• Catalytic or cofactor-dependent activity, if any, uncharacterized